In ER+, HER2- luminal breast cancers, the lowest level of PDL1 expression (7–9), a lower TML (10–12) and a relatively low level of TILs have been reported in comparison with TNBC and HER2+ tumours. This evidence concerns the gene ERBB2 and breast cancer.